rs2228314 — SREBF2 SREBF2 G1784C

SREBF2 G1784C — The Cholesterol Master Switch Variant

SREBP-2 (sterol regulatory element-binding protein 2), encoded by the SREBF2 gene on chromosome 22, is the master transcription factor of cholesterol homeostasis. It directly controls expression of HMGCR¹¹ HMGCR
HMG-CoA reductase — the rate-limiting enzyme in cholesterol biosynthesis and the target of all statin drugs, LDLR²² LDLR
the LDL receptor that clears LDL cholesterol from the bloodstream, and more than 30 other genes in the cholesterol synthesis and uptake pathways. The rs2228314 variant (G1784C) is a missense change that substitutes glycine for alanine at protein position 595 and has been linked to cardiovascular disease risk and altered cholesterol regulation across multiple populations.

The Mechanism

The Gly595Ala substitution falls in the carboxyl-terminal regulatory domain of SREBP-2, the region that physically interacts with SCAP³³ SCAP
SREBP cleavage-activating protein — the sterol sensor that escorts SREBP-2 from the ER to the Golgi for proteolytic activation. Under normal cholesterol conditions, SCAP holds SREBP-2 anchored to the endoplasmic reticulum membrane, suppressing transcriptional activity. When cellular cholesterol falls — as happens during statin treatment — SCAP escorts SREBP-2 to the Golgi, where it is cleaved and the active transcription factor enters the nucleus to upregulate HMGCR, LDLR, and other cholesterol-response genes.

The Gly595Ala change is located at a position in the C-terminal domain involved in SCAP WD-repeat interactions. Bioinformatic analysis suggests the mutation position is not strongly conserved, but in vitro studies show the Ala-595 isoform may diminish SREBF2 proteolytic cleavage⁴⁴ diminish SREBF2 proteolytic cleavage
Haas et al. — the p.A595G (C allele) polymorphism diminishes SREBF2 cleavage in vitro and is associated with higher cholesterol levels in polygenic hypercholesterolemia, potentially blunting the cholesterol-sensing feedback loop.

The Evidence

A study of early-onset myocardial infarction⁵⁵ study of early-onset myocardial infarction
Friedlander et al. SREBP-2 and SCAP isoforms and risk of early onset myocardial infarction. Atherosclerosis, 2008 in 257 women and 320 men (ages 18–59 for women, 18–49 for men) found that women homozygous for the 595A (Ala, C allele) isoform had nearly twice the risk of a first MI compared to 595G homozygotes (OR 1.95, 95% CI 1.07–3.54). In men, the 595A isoform was associated with increased MI risk per-allele (OR 1.63, 95% CI 1.26–2.12), with the effect modified by the co-inherited SCAP 2386A>G variant.

A sudden cardiac death study⁶⁶ sudden cardiac death study
Nakhjavani et al. Expression of SREBF2 and SCAP in human atheroma and association with sudden cardiac death. Thrombosis Journal, 2009 found that men carrying both the SREBF2 C allele and the SCAP G allele (rs12487736) had a 2.68-fold elevated risk of SCD (95% CI 1.07–6.71, p=0.035) compared to those carrying C allele alone, pointing to a gene-gene interaction that amplifies cardiovascular risk.

A case-control study⁷⁷ case-control study
Vargas-Alarcon et al. SREBF1c and SREBF2 gene polymorphisms and acute coronary syndrome in Mexican population. PLoS One, 2019 in 614 ACS patients and 689 healthy controls of Mexican-Amerindian descent found the G allele associated with ACS risk under recessive (OR 1.78, p=0.03) and additive (OR 1.27, p=0.04) models. The apparent reversal — G risk in Mexicans versus C risk in Europeans — likely reflects the fact that the G allele is the minor allele in Latino populations (~35%), where homozygous GG individuals represent a distinct risk stratum, while C is minor in Europeans (~26%).

A carotid intima-media thickness study⁸⁸ carotid intima-media thickness study
characterization of SREBP-2 gene polymorphisms: role in atherosclerosis. Atherosclerosis, 2003 in 655 asymptomatic men found the 1784G>C variant significantly associated with increased IMT — a marker of subclinical atherosclerosis — without detectable changes in plasma lipid levels, suggesting the variant may influence vascular risk through mechanisms beyond simple LDL elevation.

A NAFLD study⁹⁹ NAFLD study
Wang et al. Relationship of SREBP-2 rs2228314 G>C polymorphism with NAFLD in Han Chinese. Genet Test Mol Biomarkers, 2014 found homozygous GG genotype associated with increased risk of non-alcoholic fatty liver disease in 300 NAFLD cases versus 160 controls (p<0.001), suggesting the variant may also influence hepatic lipid accumulation through SREBP-2 target gene dysregulation.

ClinVar classifies the C (alternate) allele as benign based on population frequency data, with no pathogenic submissions. The clinical associations above are from GWAS and case-control studies — this variant is a risk modifier, not a disease-causing mutation.

Practical Actions

Carriers of the C allele at this locus, particularly those homozygous (CC), may have a subtly altered cholesterol-sensing feedback loop. Monitoring LDL cholesterol and tracking response to dietary changes or statin therapy is a reasonable proactive step. Those with the CC genotype may show attenuated statin response compared to GG individuals, given SREBP-2's central role in statin-induced LDLR upregulation — though the clinical evidence for this specific pharmacogenomic interaction is still emerging.

Dietary phytosterols (plant sterols/stanols from fortified foods or supplements) provide an additional cholesterol-lowering pathway that does not depend on SREBP-2 activity, making them a relevant strategy for CC genotype carriers who want to augment cholesterol management.

Interactions

The most clinically relevant interaction is with SCAP rs12487736 (2386A>G). The SCAP protein is the direct chaperone and sterol sensor for SREBP-2; variants in SCAP that alter its interaction with SREBP-2 compound the effect of this variant. Carrying risk alleles at both SREBF2 rs2228314 and SCAP rs12487736 appears to substantially elevate sudden cardiac death risk in men (OR 2.68), beyond what either variant contributes alone. This gene-gene interaction is a strong candidate for a compound action.

This variant also sits in the same cholesterol-homeostasis pathway as APOE (rs429358, rs7412). APOE E4 carriers who also carry the SREBF2 C allele may have compounded LDL clearance impairment — the APOE variant impairs LDL receptor binding affinity while the SREBF2 variant may blunt transcriptional upregulation of LDLR expression.